Prostatype Genomics AB (publ) Profit Margin

The latest profit margin for PROGEN.ST is -3737.97% as of June 2026. That compares with -6327.65% in the prior-year period — up 40.9% year over year. That is below the sector sector average of 13.2%. Investors often review this figure alongside Prostatype Genomics AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, PROGEN.ST's profit margin moved from -6327.65% to -3737.97% — a 40.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Prostatype Genomics AB (publ)'s valuation or profitability profile.

Against its sector companies, PROGEN.ST currently prints -3737.97% for profit margin, while the sector average sits near 13.2%. That is roughly 28420.3% below the sector mean. Large gaps often invite a closer look at Prostatype Genomics AB (publ)'s growth, margins, and balance sheet.

Profit Margin shows how effectively Prostatype Genomics AB (publ) converts resources into returns. At -3737.97%, PROGEN.ST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -6327.65% in the prior-year period — up 40.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PROGEN.ST's profit margin (-3737.97%), review year-over-year change from -6327.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.